Preferred Label : Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes;
NCIt synonyms : PSCA(dCH2)BBzeta-CAR T-cells; Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-cells; Autologous Anti-PSCA(dCH2)BBz-CAR T-cells;
NCIt definition : A preparation of autologous T-lymphocytes that have been immunomagnetically depleted
of CD14 myeloid cells and CD25 regulatory T-cells (Tregs), activated with anti-CD3
and anti-CD28 beads, and transduced with a self-inactivating (SIN) lentiviral vector
(LV) encoding a chimeric antigen receptor (CAR) containing a prostate stem cell antigen
(PSCA)-specific, humanized and affinity matured A11 single chain variable fragment
(scFv), a human immunoglobulin G4 (IgG4) Fc spacer lacking the CH2 domain, a human
CD4 transmembrane domain, a costimulatory human 4-1BB (CD137) cytoplasmic signaling
domain linked to the zeta chain of the human T-cell receptor (TCR)/CD3 complex (CD3zeta),
and a truncated human CD19 sequence (CD19t), with potential immunostimulating and
antineoplastic activities. Upon intravenous infusion, the autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing
T-lymphocytes recognize and induce selective toxicity in PSCA-expressing tumor cells.
PSCA, a glycosyl-phosphatidylinositol (GPI)-linked cell surface antigen, is uniquely
and highly expressed in certain cancers including bladder, pancreatic, and prostate
cancers. Co-expression of CD19t provides an inert, non-immunogenic surface marker
that allows for measurement of genetically modified cells and tracking of T-cells
following adoptive transfer. The costimulatory signaling domains improve T-cell function,
selectivity, expansion and survival.;
NCI Metathesaurus CUI : CL937402;
Origin ID : C157746;
UMLS CUI : C4763825;
Semantic type(s)
- Cell [UMLS semantic type]
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
